Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Busulfan intravenous - Otsuka Pharmaceutical

Next Previous
Drug Profile

Busulfan intravenous - Otsuka Pharmaceutical

Alternative Names: Busilvex; Busulfan - Orphan Medical; Busulfex; IV busulfan - Otsuka; KRN 246

Latest Information Update: 30 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orphan Medical; PDL BioPharma
  • Developer Kirin Holdings Company; Knight Therapeutics; Orphan Medical; Otsuka Pharmaceutical; Pierre Fabre; Tzamal Pharma
  • Class Antineoplastics; Butylene glycols; Glycols; Mesylates; Myeloablative agonists; Small molecules
  • Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haematological malignancies
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ewing's sarcoma; Haematological malignancies; Lymphoma; Neuroblastoma
  • Phase II Multiple myeloma; T-cell lymphoma

Most Recent Events

  • 09 Jan 2023 Withdrawn for Haematological malignancies in European Union (IV)
  • 27 Aug 2021 Registered for Haematological malignancies (In children) in Japan (IV)
  • 30 Mar 2020 Registered for Lymphoma (Metastatic disease) in Japan (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top